| Literature DB >> 29059504 |
Andreas Roos1,2, Rachel Thompson1, Rita Horvath1, Hanns Lochmüller1, Albert Sickmann2,3,4.
Abstract
Despite recent rapid advances in sequencing technologies, a significant proportion of patients with rare genetic disorders do not receive a genetic diagnosis after exhaustive testing, and even fewer have a potential therapeutic target identified. Taking rare neuromuscular and neurodegenerative disorders as a paradigm that can be extended to other rare Mendelian disorders, this viewpoint explores the opportunities that are brought about by the integration of genomics and proteomics, as well as the limitations and remaining challenges of this newly emerging field of proteogenomics. The relevance of combining proteomic findings with genetic results for diagnosis and gene discovery is illustrated, highlighting the insights the combined analysis provides into the underlying biology and aetiology as well as the limitations of the experimental techniques. A final discussion focuses on the importance of mechanisms to enable the sharing, reuse, and analysis of source experimental data and describes some of the international initiatives that are making progress in this area.Entities:
Keywords: data sharing; neuromuscular diseases; omics data intersection; proteogenomics; rare diseases
Mesh:
Year: 2017 PMID: 29059504 DOI: 10.1002/prca.201700073
Source DB: PubMed Journal: Proteomics Clin Appl ISSN: 1862-8346 Impact factor: 3.494